• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Preventive strategy against arsenic carcinogenesis by TRAIL pathway activation and RB activation

Research Project

Project/Area Number 19H03889
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 58020:Hygiene and public health-related: including laboratory approach
Research InstitutionKyoto Prefectural University of Medicine

Principal Investigator

Horinaka Mano  京都府立医科大学, 医学(系)研究科(研究院), 准教授 (80512037)

Co-Investigator(Kenkyū-buntansha) 安田 周祐  京都府立医科大学, 医学(系)研究科(研究院), 助教 (10643398)
酒井 敏行  京都府立医科大学, 医学(系)研究科(研究院), 特任教授 (20186993)
中尾 俊雅  京都府立医科大学, 医学(系)研究科(研究院), 博士研究員 (30829320)
Project Period (FY) 2019-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2022: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Keywordsがん予防 / ヒ素 / TRAIL / RB
Outline of Research at the Start

発がんの環境要因として、主にアジア諸国における井戸水の「ヒ素汚染」は深刻な問題であり、皮膚がん、肺がん、膀胱がんなどの発症の原因となることから、数々の疫学研究や基礎研究が実施され、ヒ素による発がん機構の解明が進められてきた。
実践的ながん予防を目指すために、がん細胞の排除に働く免疫の活性化・正常化の観点から、代表的がん抑制遺伝子である『RB』と、抗腫瘍性サイトカインである『TRAIL』に着目した。多角的な視点から予防戦略を立てることのできる「衛生学」の強みを生かし、現在までの申請者らの研究実績を基に、ヒ素発がんの予防に向けた実験的検証を行い、実践的予防法の一つを提案することを最終目標とする。

Outline of Final Research Achievements

In this study, we investigated the effects of arsenic on cellular "immunity" and the "MAPK pathway". In human lymphocytes, arsenic exposure markedly suppressed the expression of the anti-tumor cytokine TRAIL at both the mRNA and protein levels. Arsenic exposure suppressed the MAPK pathway downstream of the TCR, which regulates TRAIL expression. TRAIL expression inducers attenuated the suppression of MAPK pathway and TRAIL expression induced by arsenic exposure.
Arsenic exposure at a concentration that suppresses TRAIL expression reduced the cytotoxic effect of lymphocytes targeting human cancer cells. The MAPK pathway in human cancer cells was activated by arsenic exposure, contrary to its effect on lymphocytes. It was suggested that arsenic may comprehensively contribute to the malignant transformation.

Academic Significance and Societal Importance of the Research Achievements

アジア諸国における井戸水の「ヒ素汚染」は発がんの環境要因の一つとして深刻な問題である。実践的ながん予防を目指すためには、その機序の解明と因果関係の証明が重要である。これまでにも多くの疫学研究や基礎研究が実施され、ヒ素発がんの機構は明らかとされつつあるが、まだ十分とはいえない。本研究課題では、がん細胞を標的とすることに加え、がん細胞の排除に働く免疫の活性化・正常化を考慮に入れ、代表的がん抑制遺伝子である『RB』と、抗腫瘍性サイトカインである『TRAIL』に着目した研究を行った。本研究成果から、ヒ素発がんの予防法として、申請者らの研究実績を応用した分子標的予防戦略が提案できる可能性が示された。

Report

(5 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Annual Research Report
  • 2020 Annual Research Report
  • 2019 Annual Research Report
  • Research Products

    (39 results)

All 2023 2022 2021 2020 2019

All Journal Article (20 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 20 results,  Open Access: 15 results) Presentation (18 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer2023

    • Author(s)
      Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K
    • Journal Title

      npj Precision Oncology

      Volume: 7 Issue: 1 Pages: 12-12

    • DOI

      10.1038/s41698-023-00350-7

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Cancer-cell-selective targeting by arylcyclopropylamine-vorinostat conjugates2022

    • Author(s)
      Ota Y, Itoh Y, Kurohara T, Singh R, Elboray EE, Hu C, Zamani F, Mukherjee A, Takada Y, Yamashita Y, Morita M, Horinaka M, Sowa Y, Masuda M, Sakai T, Suzuki T
    • Journal Title

      ACS Medicinal Chemistry Letters

      Volume: 13 Issue: 10 Pages: 1568-1573

    • DOI

      10.1021/acsmedchemlett.2c00126

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Salicylic acid directly binds to ribosomal protein S3 and suppresses CDK4 expression in colorectal cancer cells2022

    • Author(s)
      Imai A, Horinaka M, Aono Y, Iizumi Y, Takakura H, Ono H, Yasuda S, Taniguchi K, Nishimoto E, Ishikawa H, Mutoh M, Sakai T
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 628 Pages: 110-115

    • DOI

      10.1016/j.bbrc.2022.08.082

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Efficacy of Low-Dose Aspirin in Colorectal Cancer Risk Prevention is Dependent on ADH1B and ALDH2 Genotype in Japanese Familial Adenomatous Polyposis Patients2022

    • Author(s)
      Mure Kanae、Ishikawa Hideki、Mutoh Michihiro、Horinaka Mano、Otani Takahiro et al.
    • Journal Title

      Cancer Research Communications

      Volume: 2 Issue: 6 Pages: 483-488

    • DOI

      10.1158/2767-9764.crc-22-0088

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Citrus limon L.-Derived Nanovesicles Show an Inhibitory Effect on Cell Growth in p53-Inactivated Colorectal Cancer Cells via the Macropinocytosis Pathway2022

    • Author(s)
      Takakura Hideki、Nakao Toshimasa、Narita Takumi、Horinaka Mano、Nakao-Ise Yukako、Yamamoto Tetsushi、Iizumi Yosuke、Watanabe Motoki、Sowa Yoshihiro、Oda Keisuke、Mori Nobuhiro、Sakai Toshiyuki、Mutoh Michihiro
    • Journal Title

      Biomedicines

      Volume: 10 Issue: 6 Pages: 1352-1352

    • DOI

      10.3390/biomedicines10061352

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells2022

    • Author(s)
      Takakura H, Horinaka M, Imai A, Aono Y, Nakao T, Miyamoto S, Iizumi Y, Watanabe M, Narita T, Ishikawa H, Mutoh M, Sakai T
    • Journal Title

      Journal of Clinical Biochemistry and Nutrition

      Volume: 70 Issue: 2 Pages: 93-102

    • DOI

      10.3164/jcbn.21-74

    • NAID

      130008165971

    • ISSN
      0912-0009, 1880-5086
    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.2022

    • Author(s)
      Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J.
    • Journal Title

      Int J Mol Sci.

      Volume: 23 Issue: 6 Pages: 2919-2936

    • DOI

      10.3390/ijms23062919

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.2022

    • Author(s)
      Tanimura K, Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, Morimoto K, Ogura Y, Takeda T, Shiotsu S, Ichikawa K, Watanabe S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Taniguchi H, Yoneda K, Matoba S, Sakai T, Uehara H, Yano S, Kusaba T, Katayama R, Takayama K.
    • Journal Title

      NPJ Precis Oncol.

      Volume: 6 Issue: 1 Pages: 5-5

    • DOI

      10.1038/s41698-021-00250-8

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells2022

    • Author(s)
      Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K
    • Journal Title

      Cancer Medicine

      Volume: 11 Issue: 4 Pages: 944-955

    • DOI

      10.1002/cam4.4504

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Oridonin inhibits SASP by blocking p38 and NF-κB pathways in senescent cells2022

    • Author(s)
      Yasuda Shusuke、Horinaka Mano、Iizumi Yosuke、Goi Wakana、Sukeno Mamiko、Sakai Toshiyuki
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 590 Pages: 55-62

    • DOI

      10.1016/j.bbrc.2021.12.098

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.2021

    • Author(s)
      Tanimura K, Yamada T, Horinaka M, Katayama Y, Fukui S, Morimoto K, Nakano T, Tokuda S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Yoneda K, Yano S, Sakai T, Takayama K.
    • Journal Title

      Cancer Lett.

      Volume: 522 Pages: 119-128

    • DOI

      10.1016/j.canlet.2021.09.018

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The combination of cigarette smoking and alcohol consumption synergistically increases reactive carbonyl species in human male plasma2021

    • Author(s)
      Mure K, Tomono S, Mure M, Horinaka M, Mutoh M, Sakai T, Ishikawa H, Wakabayashi K
    • Journal Title

      International Journal of Molecular Sciences

      Volume: 22 Issue: 16 Pages: 9043-9043

    • DOI

      10.3390/ijms22169043

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Novel RAF/MEK inhibitor CH5126766/VS‐6766 has efficacy in combination with eribulin for the treatment of triple‐negative breast cancer2021

    • Author(s)
      Ono H, Horinaka M, Sukeno M, Morita M, Yasuda S, Nishimoto E, Konishi E, Sakai T
    • Journal Title

      Cancer Science

      Volume: 112 Issue: 10 Pages: 4166-4175

    • DOI

      10.1111/cas.15071

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] γ-Glutamylcyclotransferase, a novel regulator of HIF-1α expression, triggers aerobic glycolysis2021

    • Author(s)
      Taniguchi Keiko、Kageyama Susumu、Moyama Chiami、Ando Shota、Ii Hiromi、Ashihara Eishi、Horinaka Mano、Sakai Toshiyuki、Kubota Shigehisa、Kawauchi Akihiro、Nakata Susumu
    • Journal Title

      Cancer Gene Therapy

      Volume: - Issue: 1 Pages: 37-48

    • DOI

      10.1038/s41417-020-00287-0

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Histone deacetylase inhibitor OBP-801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1-dependent apoptosis.2020

    • Author(s)
      Chihara Y, Iizumi Y, Horinaka M, Watanabe M, Goi W, Morita M, Nishimoto E, Sowa Y, Yamada T, Takayama K, Sakai T.
    • Journal Title

      Int J Oncol.

      Volume: 56 Pages: 848-856

    • DOI

      10.3892/ijo.2020.4969

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non?Small Cell Lung Cancer2020

    • Author(s)
      Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K.
    • Journal Title

      Clinical Cancer Research

      Volume: 26 Issue: 9 Pages: 2244-2256

    • DOI

      10.1158/1078-0432.ccr-19-2321

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression.2020

    • Author(s)
      Umemura S, Sowa Y, Iizumi Y, Kitawaki J, Sakai T.
    • Journal Title

      Cancer Sci.

      Volume: 111 Issue: 6 Pages: 2052-2061

    • DOI

      10.1111/cas.14414

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Very long-term treatment with a Lactobacillus probiotic preparation, Lactobacillus Casei strain Shirota, suppresses weight loss in the elderly.2020

    • Author(s)
      Ishikawa H, Mutoh M, Yoshimura K, Fujii G, Nakamura T, Takeshita T, Wakabayashi K, Sakai T.
    • Journal Title

      Nutrients

      Volume: 12 Issue: 6 Pages: 1599-1599

    • DOI

      10.3390/nu12061599

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells.2020

    • Author(s)
      Kawarazaki A, Horinaka M, Yasuda S, Kawashima H, Numajiri T, Sakai T.
    • Journal Title

      J BUON

      Volume: 25 Pages: 464-471

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Sulforaphane enhances apoptosis induced by Lactobacillus pentosus strain S-PT84 via the TNFα pathway in human colon cancer cells.2019

    • Author(s)
      Yasuda S, Horinaka M, Sakai T.
    • Journal Title

      Oncol Lett.

      Volume: 18 Pages: 4253-4261

    • DOI

      10.3892/ol.2019.10739

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] 多発性骨髄腫に対するRSK2、AKT二重阻害療法開発の理論的基盤2022

    • Author(s)
      黒田純也, 塚本拓, 堀中真野, 酒井敏行
    • Organizer
      第81回日本癌学会学術総会
    • Related Report
      2022 Annual Research Report
  • [Presentation] ALK融合遺伝子陽性肺がんにおけるEGFRシグナル活性化を介したロルラチニブ初期治療抵抗性の解明とその克服2022

    • Author(s)
      片山勇輝, 谷村恵子, 森本健司, 堀中真野, 酒井敏行, 小笹裕晃, 山田忠明
    • Organizer
      第81回日本癌学会学術総会
    • Related Report
      2022 Annual Research Report
  • [Presentation] RB活性化果実飲料の発見2022

    • Author(s)
      増田光治, 堀中真野, 安田周祐, 森田美枝, 西幹栄美, 石川秀樹, 武藤倫弘, 酒井敏行
    • Organizer
      がん予防学術大会2022
    • Related Report
      2022 Annual Research Report
  • [Presentation] 新規がん予防標的GGCTは、がん細胞にHIF-1α発現を誘導して好気的解糖を促進する2022

    • Author(s)
      谷口恵香, 影山進, 茂山千愛美, 安藤翔太, 飯居宏美, 芦原英司, 堀中真野, 酒井敏行, 窪田成寿, 河内明宏, 中田晋
    • Organizer
      がん予防学術大会2022
    • Related Report
      2022 Annual Research Report
  • [Presentation] サリチル酸はヒト大腸がん細胞のRPS3に結合し、CDK4発現抑制と細胞周期のG1期停止を誘導する2022

    • Author(s)
      今井綾香, 堀中真野, 青野裕一, 飯泉陽介, 高倉秀樹, 小野寿子, 谷口恵香, 安田周祐, 西幹栄美, 石川秀樹, 武藤倫弘, 酒井敏行
    • Organizer
      がん予防学術大会2022
    • Related Report
      2022 Annual Research Report
  • [Presentation] 延命草成分オリドニンはp38とNF-κBを介して老化関連分泌現象を阻害する2022

    • Author(s)
      安田周祐, 堀中真野, 飯泉陽介, 後居和佳奈, 助野真美子, 酒井敏行
    • Organizer
      がん予防学術大会2022
    • Related Report
      2022 Annual Research Report
  • [Presentation] ALK融合遺伝子陽性肺がんにおけるJNK/c-Jun経路活性化を介したALK阻害薬抵抗性機構の解明2022

    • Author(s)
      谷村恵子, 堀中真野, 米田和恵, 矢野聖二, 酒井敏行, 山田忠明
    • Organizer
      第26回日本がん分子標的治療学会学術集会
    • Related Report
      2022 Annual Research Report
  • [Presentation] ALK融合遺伝子陽性肺がんにおけるEGFRシグナル活性化を介したLorlatinibの初期治療抵抗性機構の解明2022

    • Author(s)
      片山勇輝, 谷村恵子, 森本健司, 堀中真野, 酒井敏行, 山田忠明
    • Organizer
      第26回日本がん分子標的治療学会学術集会
    • Related Report
      2022 Annual Research Report
  • [Presentation] 延命草成分オリドニンはp38とNF-kBを介して老化関連分泌現象を阻害する2022

    • Author(s)
      安田周祐, 堀中真野, 飯泉陽介, 後居和佳奈, 助野真美子, 酒井敏行
    • Organizer
      第21回分子予防環境医学研究会大会
    • Related Report
      2021 Annual Research Report
  • [Presentation] EGFR-T790M変異陽性肺がんの生物学的特徴に関する基礎的検討2021

    • Author(s)
      片山勇輝, 西岡直哉, 大倉直子, 森本健司, 谷村恵子, 堀中真野, 酒井敏行, 矢野聖二, 山田忠明
    • Organizer
      第25回日本がん分子標的治療学会学術集会
    • Related Report
      2021 Annual Research Report
  • [Presentation] ALK肺癌におけるALKとHER3の共阻害による新たな治療戦略2021

    • Author(s)
      谷村恵子, 山田忠明, 米田和恵, 堀中真野, 酒井敏行, 上原久典, 矢野聖二, 片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 新規がん予防標的GGCTは、がん細胞にHIF-1α発現を誘導しワールブルク効果を促進する2021

    • Author(s)
      谷口恵香, 影山進, 茂山千愛美, 安藤翔太, 飯居宏美, 芦原英司, 堀中真野, 酒井敏行, 窪田成寿, 河内明宏, 中田晋
    • Organizer
      第20回分子予防環境医学研究会大会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 「先制医療」の実現に向けた戦略的研究2021

    • Author(s)
      堀中真野, 酒井敏行
    • Organizer
      第91回日本衛生学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 新規がん予防標的GGCTは、がん細胞にHIF-1α発現を誘導して好気性解糖を促進する2021

    • Author(s)
      谷口恵香, 影山進, 茂山千愛美, 安藤翔太, 飯居宏美, 芦原英司, 堀中真野, 酒井敏行, 河内明宏, 中田晋
    • Organizer
      第91回日本衛生学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] アスピリン、メサラジン併用による大腸がん予防効果の検討2020

    • Author(s)
      高倉英樹,堀中真野,今井綾香,武藤倫弘,酒井敏行
    • Organizer
      第90回日本衛生学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] スリンダク代謝体スリンダクスルホンの大腸癌細胞に対する新規標的分子の同定と作用機序の解析2019

    • Author(s)
      堀中真野,青野裕一,飯泉陽介,渡邉元樹,酒井敏行
    • Organizer
      第23回日本がん分子標的治療学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] スリンダク代謝体であるスリンダクスルホンによる大腸腺腫形成抑制作用の機序解明に向けた新規標的分子の同定2019

    • Author(s)
      堀中真野,青野裕一,飯泉陽介,安田周祐,渡邉元樹,谷口知行,酒井敏行
    • Organizer
      第26回日本がん予防学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting VDAC1 and VDAC2.2019

    • Author(s)
      青野裕一,堀中真野,飯泉陽介,安田周祐,渡邉元樹,酒井敏行
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Patent(Industrial Property Rights)] RB活性化食品組成物2022

    • Inventor(s)
      酒井 敏行、堀中 真野、増田 光治
    • Industrial Property Rights Holder
      京都府公立大学法人、築野食品工業株式会社
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2022-036535
    • Filing Date
      2022
    • Related Report
      2021 Annual Research Report

URL: 

Published: 2019-04-18   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi